Illumina, Inc. (NASDAQ:ILMN) Position Cut by California Public Employees Retirement System

California Public Employees Retirement System decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 321,476 shares of the life sciences company’s stock after selling 29,373 shares during the period. California Public Employees Retirement System owned approximately 0.22% of Illumina worth $76,003,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ILMN. Financial Gravity Companies Inc. bought a new stake in shares of Illumina during the 4th quarter valued at $106,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Illumina in the 1st quarter valued at $113,000. SeaCrest Wealth Management LLC bought a new stake in shares of Illumina in the 4th quarter valued at $154,000. Captrust Financial Advisors bought a new stake in shares of Illumina in the 4th quarter valued at $165,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Illumina by 113.9% in the 4th quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock valued at $168,000 after buying an additional 410 shares in the last quarter. Institutional investors own 90.87% of the company’s stock.

In related news, EVP Marc Stapley sold 1,446 shares of the firm’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $285.18, for a total value of $412,370.28. Following the completion of the sale, the executive vice president now directly owns 9,562 shares in the company, valued at approximately $2,726,891.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles Dadswell sold 116 shares of the firm’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $230.91, for a total transaction of $26,785.56. Following the completion of the sale, the senior vice president now owns 7,875 shares of the company’s stock, valued at $1,818,416.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,771 shares of company stock valued at $10,339,278. Company insiders own 0.54% of the company’s stock.



ILMN has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 19th. Morgan Stanley upped their price objective on shares of Illumina from $170.00 to $180.00 and gave the company an “underweight” rating in a research report on Wednesday, April 25th. Barclays upgraded shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 price objective for the company in a research report on Monday, May 7th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research report on Monday, April 16th. Finally, ValuEngine cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Thursday, April 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company. Illumina has a consensus rating of “Buy” and a consensus target price of $253.36.

Illumina stock opened at $290.16 on Friday. Illumina, Inc. has a one year low of $167.98 and a one year high of $293.15. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.41. The stock has a market cap of $41.77 billion, a PE ratio of 72.54, a price-to-earnings-growth ratio of 3.04 and a beta of 0.88.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.43. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The company had revenue of $782.00 million during the quarter, compared to the consensus estimate of $744.30 million. During the same period in the prior year, the business posted $0.64 EPS. The company’s quarterly revenue was up 30.8% on a year-over-year basis. sell-side analysts expect that Illumina, Inc. will post 4.86 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply